MMSI Merit Medical Systems Inc.

Merit Medical Launches Smallest and Shortest Configuration of Elation® Pulmonary Balloon Dilator to Help Meet Critical Patient Need

Merit Medical Launches Smallest and Shortest Configuration of Elation® Pulmonary Balloon Dilator to Help Meet Critical Patient Need

Only balloon configuration specifically designed to dilate small airways, providing minimally invasive treatment to patients with lung obstructions

SOUTH JORDAN, Utah, July 20, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced U.S. commercial release of the smallest and shortest configuration in its Elation® Pulmonary Balloon Dilator portfolio.

The unique balloon size fills a critical need in the pulmonary care space. Historically, physicians have relied on single-stage, cardiovascular balloons that were often too large and too long for use in smaller airways. The new Elation balloon—part of Merit’s expanded range of multi-stage pulmonary balloon configurations—allows physicians to accurately match balloon diameter and length to specific small airways in the lungs, bringing treatment options to more patients.

Airway obstructions (blockages) can be life-threatening and may occur directly from trauma, malignancy (cancer), and infection. Airway dilation provides a reliable treatment in both malignant and benign (non-cancerous) situations, restoring airway patency and reducing shortness of breath, which allows healing and helps to improve patients’ quality of life.  

“This is the first dilation balloon with a pulmonary indication that has an appropriate size and length for smaller airways,” said Dr. Ali Sadoughi, director of interventional pulmonology and bronchoscopy services at Montefiore Medical Center. “This new configuration helps me safely dilate challenging strictures, including those in short airways at the lobar and segmental levels without fear of over-dilating past the intended site.”

“The new Elation Pulmonary Balloon Dilator is the only one on the market that allows me to safely and accurately balloon dilate small distal airways,” said Dr. Ankit Dhamija, assistant professor of cardiothoracic surgery at Stony Brook Medicine.

The multi-stage balloon configuration measures 4-5-6 mm x 1.5 cm. In addition to its unique sizing, its kink-resistant catheter allows for several insertions and dilations during a single procedure, potentially eliminating the need to use a second balloon.

Learn more about the .

The Elation family of products belongs to a broader portfolio of pulmonary innovations that offers airway stents, guide wires, bronchoscopy kits, balloon dilators, inflation devices, and accessories used to provide interventional and palliative treatment options.

“The new Elation balloon configuration is a significant addition to our Pulmonary portfolio, because it provides a therapeutic option to patients who would otherwise have none,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “It is a prime example of how our focus is on understanding the needs of physicians and their patients and bringing innovative solutions to market.”

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 600 individuals. Merit employs approximately 6,500 people worldwide.

TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc. and its subsidiaries in the United States and other jurisdictions.

CONTACTS 

PR/Media Inquiries 

Sarah Comstock 

Merit Medical 

|

INVESTOR INQUIRIES 

Mike Piccinino, CFA, IRC 

Westwicke - ICR 

|



EN
20/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merit Medical Systems Inc.

Merit Medical Systems Inc: 1 director

A director at Merit Medical Systems Inc sold 10,000 shares at 95.190USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

 PRESS RELEASE

Merit Medical Acquires Biolife Delaware, L.L.C.

Merit Medical Acquires Biolife Delaware, L.L.C. Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports.Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profileMerit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acq...

 PRESS RELEASE

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-I...

Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.Approval was supported by superior 12-month target lesion primary patency (70.1%) and access circuit primary patency (58.1%) in the randomized arm of the trial. SOUTH JORDAN, Utah, May 06, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the Wrapsody Cell-Impermeable Endoprosthesis (CIE) received regulator...

 PRESS RELEASE

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Ar...

Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months. SOUTH JORDAN, Utah, May 05, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that the 12-month results from the single-arm cohort of the WAVE trial were presented at the annual Charing Cross Symposium ...

 PRESS RELEASE

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year...

Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance First Quarter Highlights† Reported revenue of $355.4 million, up 9.8%Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectivelyGAAP operating margin of 11.5%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.3%, compared to 17.0% in prior year periodGAAP EPS $0.49, up 2.0%Non-GAAP EPS* $0.86, up 14.8%Free cash flow* generation of $19.5 million, down 20.5% † Comparisons above are calculated for the current quarter compared with the first quarter o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch